Osmertinib neoadjuvant for treating EGFR mutation positive resectable non-squamous non- small cell lung cancer

Osimertinib is in phase III clinical development as a neoadjuvant treatment for epidermal growth factor receptor mutation (EGFRm) positive, resectable (stage II -IIIB), non-squamous, non-small cell lung cancer (NSCLC). Lung cancer is one of the most common and serious types of cancer and NSCLC is the most common type of lung cancer. A neoadjuvant treatment is administered before the main treatment. Resectable cancer means that the cancer can be removed by surgery, which means the cancer is normally in earlier stages. A proportion of patients with NSCLC have mutations to the protein epidermal growth factor receptor (EGFR) which controls cell growth. A treatment that lowers the risk of recurrence in this cancer is needed.